A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates CART Proliferation, Differentiation, and Tumor Killing
CART therapy is revolutionizing modern cancer therapy, with two anti-CD19 CARTs FDA-approved for relapsed/refractory B cell lymphoma/leukemia and many other CARTs for solid and liquid tumors currently undergoing clinical trials. However, in current clinical practice, suboptimal CART persistence and tumor killing permit tumor cell escape and, ultimately, disease relapse. Reasoning that a pro-lymphoid growth factor could promote CART efficacy, we supplemented UCART infusion with subcutaneous injections of the long-acting form of recombinant human interleukin-7 fused with hybrid Fc (rhIL-7-hyFc, NT-I7) in vivo using a CD19+ lymphoma xenograft model.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Matthew Cooper, Karl William Staser, Jessica Niswonger, Julie K. Ritchey, Byung Ha Lee, Jaehan Park, John F. DiPersio Tags: 223 Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Leukemia | Lymphoma | Transplants